Axogen, Inc. (AXGN)
NASDAQ: AXGN · Real-Time Price · USD
15.98
+0.58 (3.77%)
At close: Sep 5, 2025, 4:00 PM
15.84
-0.14 (-0.88%)
After-hours: Sep 5, 2025, 6:00 PM EDT
Axogen Revenue
Axogen had revenue of $56.66M in the quarter ending June 30, 2025, with 18.26% growth. This brings the company's revenue in the last twelve months to $203.27M, up 17.17% year-over-year. In the year 2024, Axogen had annual revenue of $187.34M with 17.81% growth.
Revenue (ttm)
$203.27M
Revenue Growth
+17.17%
P/S Ratio
3.43
Revenue / Employee
$449,715
Employees
452
Market Cap
736.66M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 187.34M | 28.33M | 17.81% |
| Dec 31, 2023 | 159.01M | 20.43M | 14.74% |
| Dec 31, 2022 | 138.58M | 11.23M | 8.81% |
| Dec 31, 2021 | 127.36M | 15.06M | 13.41% |
| Dec 31, 2020 | 112.30M | 5.59M | 5.24% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
AXGN News
- 11 days ago - Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft - GlobeNewsWire
- 24 days ago - Axogen: Broad Range Of Outcomes Still Present, Opting To Remain Sidelined - Seeking Alpha
- 4 weeks ago - Axogen, Inc. (AXGN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference - GlobeNewsWire
- 6 weeks ago - Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025 - GlobeNewsWire
- 3 months ago - Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference - GlobeNewsWire
- 4 months ago - Axogen, Inc. (AXGN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Axogen, Inc. Reports 2025 First Quarter Financial Results - GlobeNewsWire